Oncolytics Biotech (ONCY) Net Income (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Net Income of -$29.1 million for Q3 2025, down 316.57% year-over-year from $13.5 million in Q3 2024, and down 306.65% quarter-over-quarter from $14.1 million in Q2 2025.
Oncolytics Biotech (ONCY) Net Income (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Net Income for 17 consecutive years, with -$29.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Income fell 316.57% year-over-year to -$29.1 million; the TTM figure through Dec 2025 stood at -$19.7 million (down 188.56% YoY), while the FY2025 annual figure was -$28.8 million, down 224.17% from the prior year.
- Net Income slipped to -$29.1 million in Q3 2025 per ONCY's latest filing, from $14.1 million in the prior quarter.
- Across five years, Net Income topped out at $39.7 million in Q4 2024 and bottomed at -$29.1 million in Q3 2025.
- Historically, Net Income has averaged $1.3 million across 5 years, with a median of -$3.9 million in 2021.
- Annual changes were most pronounced in 2021 — Net Income slumped 1805.46% — and 2024, when it soared 1267.27%.
- Oncolytics Biotech's Net Income stood at $6.1 million in 2021, then surged by 392.59% to $30.3 million in 2022, then tumbled by 90.42% to $2.9 million in 2023, then soared by 1267.27% to $39.7 million in 2024, then sank by 173.48% to -$29.1 million in 2025.
- Business Quant data shows ONCY's Net Income at -$29.1 million in Q3 2025, $14.1 million in Q2 2025, and -$4.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.44 Mn |
| Sep 30, 2025 | -29.14 Mn |
| Jun 30, 2025 | 14.10 Mn |
| Mar 31, 2025 | -4.66 Mn |
| Dec 31, 2024 | 39.66 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -5.31 Mn |
| Mar 31, 2024 | -5.12 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 7.40 Mn |
| Jun 30, 2023 | 5.54 Mn |
| Mar 31, 2023 | 4.76 Mn |
| Dec 31, 2022 | 30.29 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -4.00 Mn |
| Mar 31, 2022 | 5.35 Mn |
| Dec 31, 2021 | 6.15 Mn |
| Sep 30, 2021 | -3.87 Mn |
| Jun 30, 2021 | -5.89 Mn |
| Mar 31, 2021 | -5.08 Mn |